|
49 Companies |
|
54 Products |
|
54 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
194 News |
|
| «1234» |
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 14, 2015
P2, N=43, Completed, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting --> Completed
- || humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- | Vaxira (racotumomab) / Eurofarma, Recombio
Trial completion: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - Jun 29, 2015
P1, N=15, Completed, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - Jun 18, 2015
P1/2, N=8, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed | N=44 --> 8 | Trial primary completion date: Feb 2016 --> Jun 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P1 trial: Ewing/Allo: Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma (clinicaltrials.gov) - Jun 15, 2015
P1, N=10, Recruiting, Sponsor: University of Louisville
- Trial primary completion date: Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques) (clinicaltrials.gov) - Jun 11, 2015
P0, N=24, Recruiting, Sponsor: Soul Medicine Institute
Recruiting --> Completed | N=44 --> 8 | Trial primary completion date: Feb 2016 --> Jun 2015 Trial primary completion date: Nov 2015 --> Nov 2017
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2015 --> Nov 2017 Active, not recruiting --> Completed | N=120 --> 78
- ||| Biomarker, Trial completion: Biomarkers in Tissue Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 12, 2015
P=N/A, N=166, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=120 --> 78 Active, not recruiting --> Completed
- ||| Enrollment open, Trial primary completion date: Study of Tumor Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=200, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2010 --> Jan 2100
- | temozolomide / Generic mfg.
Trial completion: Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2010 --> Jan 2100 No longer recruiting --> Completed
- imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (clinicaltrials.gov) - Apr 15, 2015
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- irinotecan / Generic mfg., sorafenib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors (clinicaltrials.gov) - Feb 27, 2015
P1, N=17, Completed, Sponsor: HMeany
Active, not recruiting --> Completed Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Aug 2014 --> Jan 2015
- Seprehvir (HSV1716) / Sorrento
Enrollment change, Trial primary completion date: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Feb 5, 2015
P1, N=18, Recruiting, Sponsor: Nationwide Children's Hospital
Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Aug 2014 --> Jan 2015 N=15 --> 18 | Trial primary completion date: Aug 2014 --> Dec 2016
- | plerixafor / Generic mfg.
Enrollment closed: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Jan 17, 2015
P1/2, N=46, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
N=15 --> 18 | Trial primary completion date: Aug 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Jan 15, 2015
P1, N=6, Completed, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=15 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date, Metastases: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Dec 24, 2014
P1, N=6, Active, not recruiting, Sponsor: City of Hope Medical Center
N=15 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Feb 2015 --> Feb 2016
- melphalan / Generic mfg., busulfan / Generic mfg.
Trial initiation date: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 13, 2014
P1, N=10, Recruiting, Sponsor: University of Louisville
Trial primary completion date: Feb 2015 --> Feb 2016 Initiation date: Oct 2013 --> Apr 2013
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Dec 5, 2014
P1, N=15, Recruiting, Sponsor: University of Louisville
Initiation date: Oct 2013 --> Apr 2013 Trial primary completion date: Aug 2014 --> Aug 2015
- Trial primary completion date: Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques) (clinicaltrials.gov) - Nov 18, 2014
P0, N=24, Recruiting, Sponsor: Soul Medicine Institute
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- Trial primary completion date: Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques) (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=100, Recruiting, Sponsor: Soul Medicine Institute
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jun 2014 --> Jun 2016
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Nov 2014 --> Apr 2015
- || Talzenna (talazoparib) / Pfizer
Enrollment closed, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Oct 10, 2014
P1, N=85, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Yondelis (trabectedin) / PharmaMar, J&J
Trial completion: Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=50, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | vinblastine / Generic mfg., celecoxib oral / Generic mfg.
Trial completion, Combination therapy, Metastases: Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=38, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Phase classification, Enrollment change, Trial primary completion date: Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=7, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009
- Trial termination, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=7, Terminated, Sponsor: City of Hope Medical Center
Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009 Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor.
- ||| Trial completion: Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=294, Completed, Sponsor: Children's Oncology Group
Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor. Active, not recruiting --> Completed
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Trial completion: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 1, 2014
P1, N=21, Completed, Sponsor: Merckle GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | vinorelbine tartrate / Generic mfg.
Trial completion: Vinorelbine in Treating Children With Recurrent or Refractory Cancers (clinicaltrials.gov) - Jul 28, 2014
P2, N=50, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion, Enrollment change: Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Jul 24, 2014
P1, N=16, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 16
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=24 --> 16 Trial primary completion date: Aug 2014 --> Nov 2014
- Vaxira (racotumomab) / Eurofarma, Recombio
Enrollment closed, Trial primary completion date: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - Jul 17, 2014
P1, N=15, Active, not recruiting, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014
- midazolam hydrochloride / Generic mfg., cefuroxime / Generic mfg.
Clinical: Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=50, Completed, Sponsor: Benazir Bhutto Hospital, Rawalpindi
- Trial primary completion date, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014 Trial primary completion date: Jun 2014 --> Nov 2013
- Trial termination, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Trial primary completion date: Jun 2014 --> Nov 2013 Active, not recruiting --> Terminated; Study did not reach primary objective; study did not accrue enough patients.
- Enrollment change, Trial termination, Trial primary completion date, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Study did not reach primary objective; study did not accrue enough patients. N=20 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Nov 2013; Study did not reach primary objective; study did not accrue enough patients.
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor (clinicaltrials.gov) - Jun 19, 2014
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
N=20 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Nov 2013; Study did not reach primary objective; study did not accrue enough patients. N=48 --> 34
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=48 --> 34 N=92 --> 30
- Rytelo (imetelstat) / Geron
Trial initiation date: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=92 --> 30 Initiation date: Jan 2014 --> Jun 2014
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - May 19, 2014
P1, N=21, Active, not recruiting, Sponsor: Merckle GmbH
Initiation date: Jan 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- Trial primary completion date: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma (clinicaltrials.gov) - May 12, 2014
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2014 --> Mar 2016
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2014 --> Mar 2016 N=160 --> 114
- cixutumumab (IMC A12) / Eli Lilly
Trial completion: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
N=160 --> 114 Active, not recruiting --> Completed
- Rytelo (imetelstat) / Geron
Trial withdrawal: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Withdrawn N=110 --> 0
- | NN1213 / Novo Nordisk
Trial completion: Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=10, Completed, Sponsor: Milton S. Hershey Medical Center
N=110 --> 0 Recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=70, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed